OverviewSuggest Edit

Cipla is a global pharmaceutical company, which offers active pharmaceutical ingredients and formulations in various therapeutic areas, such as women’s health, cardiovascular, children’s health, dermatology and cosmeceuticals, diabetes, HIV-AIDS, hepatitis, oncology, infectious diseases and critical care, malaria, neurosciences, ophthalmology, osteoporosis, respiratory, and urology. The Company also provides veterinary products, including anti-infectives, anti-inflammatories, anti-thyroids, immunosuppressants, parasiticides, nutraceuticals, and feed additives for various animals.

TypePublic
Founded1935
HQMumbai, IN
Websitecipla.com
Employee Ratings3.9

Latest Updates

Employees (est.) (Apr 2018)23,043
Job Openings41
Share Price (Jun 2021)₹967.8(+3%)
Cybersecurity ratingDMore

Key People/Management at Cipla

K.a. Hamied

K.a. Hamied

Founder
Umang Vohra

Umang Vohra

Managing Director & Global Chief Executive Officer
Y. K. Hamied

Y. K. Hamied

Non-Executive Chairman
M. K. Hamied

M. K. Hamied

Vice-Chairman
Kedar Upadhye

Kedar Upadhye

Global Chief Financial Officer
Geena Malhotra

Geena Malhotra

Global Head - Integrated Product Development
Show more

Cipla Office Locations

Cipla has offices in Mumbai, Central Islip, South Melbourne, Nairobi and in 7 other locations
Mumbai, IN (HQ)
1, Peninsula Spenta, Mathuradas Mill Compound, Senapati Bapat Marg, Lower Parel
Mumbai, IN
2nd Floor, Bldg, 5, LBS Rd, Suryanagar No. 2, HMPL Surya Nagar, Vikhroli West
South Melbourne, AU
Level 1/132 Albert Rd
Nairobi, KE
Chiromo Road Purshottam Place
Cape Town, ZA
Mispel Street, Bellville
Durban, ZA
18 The Boulevard, Westway Office Park, Dawncliffe
Show all (13)

Cipla Financials and Metrics

Cipla Revenue

Market capitalization (11-Jun-2021)

780.6b

Closing stock price (11-Jun-2021)

967.8
Cipla's current market capitalization is ₹780.6 b.
Show all financial metrics

Cipla Cybersecurity Score

Cybersecurity ratingPremium dataset

D

61/100

SecurityScorecard logo

Cipla Environment, Social & Governance (ESG) Ratings

CSRHub ESG ratingPremium dataset

50-59

out of 100

CSRHub logo

Cipla Online and Social Media Presence

Embed Graph

Cipla News and Updates

Cipla seeks price capping waiver, indemnity as it readies to pay $1B advance for Moderna vaccine

Cipla, which is in advanced talks with Moderna to bring its single-dose COVID-19 vaccine to India, has appealed to the government to provide confirmation on four critical points: exemption from price restriction, indemnification, bridging trial waiver, and basic customs duty exemption.

World Asthma Spacers Market Outlook 2021-2025, Featuring Cipla Limited, GlaxoSmithKline plc (GSK), Koninklijke Philips N.V., and Lupin Limited

DUBLIN, May 24, 2021 /PRNewswire/ -- The "Global Asthma Spacers Market: Size & Forecast with Impact Analysis of COVID-19 (2021-2025)" report has been added to ResearchAndMarkets.com's offering. The global asthma spacers market has increased at a significant CAGR during the years...

Cipla Q4 Review: Analysts See Covid-19 Products, U.S. Inhaler Pipeline Key Catalysts

Cipla shares are on a three-session gaining streak.

Share Market Live: SGX Nifty Climbs Amid Positive Asian Trade; Dr. Reddy’s, L&T, Cipla

Catch all live updates on share prices, index moves, corporate announcements and more from Indian stock markets today.

Global Corticosteroids Market Report 2021 Featuring Major Players - Sumitomo, Pfizer, Novartis, Merck, Sanofi, Johnson and Johnson, GSK, AstraZeneca, Cipla, and LEO Pharma

Dublin, May 13, 2021 (GLOBE NEWSWIRE) -- The "Corticosteroids Global Market Report 2021: COVID-19 Implications and Growth to 2030" report has been added to ResearchAndMarkets.com's offering. Major players in the corticosteroids therapy market are Sumitomo, Pfizer, Novartis, Merck, Sanofi, Johnson …

Eli Lilly inks pacts for Baricitinib with Sun Pharma, Cipla, Lupin for COVID-19 treatment in India

Baricitinib is currently registered in India for the treatment of moderate to severe active rheumatoid arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying anti-rheumatic drugs.
Show more

Cipla Blogs

Humane Approach To Health Care

It’s been a week of accolades for scientist and chairman of Cipla, Dr Yusuf K Hamied, who received the Indore Management Association Lifetime Achievement Award for 2018 last Friday. “It was attended by 5,000 management students and 1,000 business executives, and was really quite impressive,” he said…

Patents and patients

Of patents and patients Pharmaceutical giant Cipla’s archive is worth emulating for all legacy companies. This diarist toured it last week and was surprised to see the effort gone into chronicling the company’s eight-decade-long journey. A visitors’ book from 1939, signed by both Mahatma Gandhi and …

Of Patents and Patients

Pharmaceutical giant Cipla’s archive is worth emulating for all legacy companies. This diarist toured it last week and was surprised to see the effort gone into chronicling the company’s eight-decade-long journey. A visitors’ book from 1939, signed by both Mahatma Gandhi and Sardar Vallabhbhai Patel…

In Remote Villages, Surprising New Measures Save Children With Malaria

Malaria quickly kills toddlers. But rapid diagnostic tests, a new suppository drug and bicycle ambulances can buy enough time to get stricken children to hospitals. During malaria season, children who live in remote villages are at tremendous risk. When parasites transmitted by mosquitoes swarm into…

A first in Morocco: CIPLA MAROC opens an inhaler manufacturing plant in the Rabat region for an investment of 60 MDH

Inaugurated by MM. Anas Doukali and MM. Moulay Hafid Elalamy, the plant will produce 1.5 million metered-dose inhalers annually Rabat, Morocco, October 13, 2018: Cipla Maroc, subsidiary of the leading global pharmaceutical company Cipla Ltd, today announced the official opening of its manufacturing …

Guardian story on RAS

Internally administered medicine allows crucial window of time for children in remote areas to reach healthcare facilities A suppository form of a malaria-fighting drug could provide a lifeline to children in rural areas, drastically cutting the number of deaths caused by the disease. A study in rur…
Show more

Cipla Frequently Asked Questions

  • When was Cipla founded?

    Cipla was founded in 1935.

  • Who are Cipla key executives?

    Cipla's key executives are K.a. Hamied, Umang Vohra and Y. K. Hamied.

  • How many employees does Cipla have?

    Cipla has 23,043 employees.

  • Who are Cipla competitors?

    Competitors of Cipla include Abbott India, Pfizer and Par Pharmaceutical.

  • Where is Cipla headquarters?

    Cipla headquarters is located at 1, Peninsula Spenta, Mathuradas Mill Compound, Senapati Bapat Marg, Lower Parel, Mumbai.

  • Where are Cipla offices?

    Cipla has offices in Mumbai, Central Islip, South Melbourne, Nairobi and in 7 other locations.

  • How many offices does Cipla have?

    Cipla has 13 offices.